CA 102
Alternative Names: CA-102Latest Information Update: 23 Aug 2023
At a glance
- Originator Curigin
- Class Antineoplastics; Gene therapies; Immunotherapies; Small interfering RNA
- Mechanism of Action MTOR protein inhibitors; RNA interference; STAT3 transcription factor expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Bladder cancer; Pancreatic cancer